NYSE:ABT - Abbott Laboratories Stock Price, Forecast & News

Abbott Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABT."

Abbott Laboratories announced a quarterly dividend on Friday, December 13th. Stockholders of record on Wednesday, January 15th will be paid a dividend of $0.36 per share on Friday, February 14th. This represents a $1.44 dividend on an annualized basis and a dividend yield of 1.62%. The ex-dividend date of this dividend is Tuesday, January 14th. This is a positive change from Abbott Laboratories's previous quarterly dividend of $0.32. View Abbott Laboratories' Dividend History.

Abbott Laboratories (NYSE:ABT) issued its quarterly earnings results on Wednesday, October, 16th. The healthcare product maker reported $0.84 earnings per share for the quarter, hitting the Zacks' consensus estimate of $0.84. The healthcare product maker had revenue of $8.08 billion for the quarter, compared to analysts' expectations of $8.10 billion. Abbott Laboratories had a net margin of 10.50% and a return on equity of 17.65%. The firm's quarterly revenue was up 5.5% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.75 EPS. View Abbott Laboratories' Earnings History.

Abbott Laboratories is scheduled to release their next quarterly earnings announcement on Wednesday, January 22nd 2020. View Earnings Estimates for Abbott Laboratories.

Abbott Laboratories will be holding an earnings conference call on Wednesday, January 22nd at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

16 brokers have issued 12 month price targets for Abbott Laboratories' shares. Their forecasts range from $81.00 to $101.00. On average, they expect Abbott Laboratories' stock price to reach $91.27 in the next twelve months. This suggests a possible upside of 2.6% from the stock's current price. View Analyst Price Targets for Abbott Laboratories.

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Abbott Laboratories in the last year. There are currently 2 sell ratings, 4 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Abbott Laboratories.

Media headlines about ABT stock have trended positive recently, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Abbott Laboratories earned a coverage optimism score of 3.0 on InfoTrie's scale. They also gave media stories about the healthcare product maker a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Abbott Laboratories.

Some companies that are related to Abbott Laboratories include Medtronic (MDT), Stryker (SYK), Becton Dickinson and (BDX), Intuitive Surgical (ISRG), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), IDEXX Laboratories (IDXX), ResMed (RMD), DexCom (DXCM), Teleflex (TFX), Hologic (HOLX), Varian Medical Systems (VAR), Steris (STE) and Insulet (PODD).

Based on aggregate information from My MarketBeat watchlists, some companies that other Abbott Laboratories investors own include AbbVie (ABBV), AT&T (T), Johnson & Johnson (JNJ), Cisco Systems (CSCO), NVIDIA (NVDA), Home Depot (HD), Walt Disney (DIS), Pfizer (PFE), Intel (INTC) and Micron Technology (MU).

Abbott Laboratories' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Gateway Investment Advisers LLC (0.05%), Hexavest Inc. (0.04%), Nisa Investment Advisors LLC (0.04%), Welch & Forbes LLC (0.04%), Johanson Financial Advisors Inc. (0.03%) and Park National Corp OH (0.03%). Company insiders that own Abbott Laboratories stock include Andrew H Lane, Brian B Yoor, Brian J Blaser, Daniel Gesua Sive Salvadori, Daniel J Starks, Hubert L Allen, Jaime Contreras, Jared Watkin, John G Stratton, John M Capek, Joseph J Manning, Michael J Pederson, Miles D White, Randel William Woodgrift, Roger Bird, Sally E Blount, Sharon J Bracken and Stephen R Fussell. View Institutional Ownership Trends for Abbott Laboratories.

ABT stock was sold by a variety of institutional investors in the last quarter, including Calamos Advisors LLC, OLD National Bancorp IN, Artemis Investment Management LLP, Meag Munich Ergo Kapitalanlagegesellschaft MBH, Huntington National Bank, Hexavest Inc., Abner Herrman & Brock LLC and State of Alaska Department of Revenue. Company insiders that have sold Abbott Laboratories company stock in the last year include Brian B Yoor, Brian J Blaser, Daniel Gesua Sive Salvadori, Hubert L Allen, Jaime Contreras, Jared Watkin, John M Capek, Joseph J Manning, Michael J Pederson, Miles D White, Randel William Woodgrift, Roger Bird, Sally E Blount, Sharon J Bracken and Stephen R Fussell. View Insider Buying and Selling for Abbott Laboratories.

ABT stock was purchased by a variety of institutional investors in the last quarter, including Johanson Financial Advisors Inc., Garnet Equity Capital Holdings Inc., Rockland Trust Co., United Services Automobile Association, Donaldson Capital Management LLC, Advisors Capital Management LLC, Red Spruce Capital LLC and Commerzbank Aktiengesellschaft FI. Company insiders that have bought Abbott Laboratories stock in the last two years include Daniel J Starks, John G Stratton and Randel William Woodgrift. View Insider Buying and Selling for Abbott Laboratories.

Shares of ABT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ABT stock can currently be purchased for approximately $89.00.

Abbott Laboratories has a market capitalization of $157.39 billion and generates $30.58 billion in revenue each year. The healthcare product maker earns $2.37 billion in net income (profit) each year or $2.88 on an earnings per share basis. Abbott Laboratories employs 103,000 workers across the globe.View Additional Information About Abbott Laboratories.

The official website for Abbott Laboratories is http://www.abbott.com/.

Abbott Laboratories' mailing address is 100 ABBOTT PARK ROAD D-322 AP6D, ABBOTT PARK IL, 60064. The healthcare product maker can be reached via phone at 224-667-6100.